Utah is currently home to 1198 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Project Talk Trial: Engaging Underserved Communities in End-of-life Conversations
NCT04612738
Recruiting
Compared to the general population, individuals from underserved communities are more likely to receive low quality end-of-life care and unwanted, costly and burdensome treatments due in part to a lack of advance care planning (ACP; the process of discussing wishes for end-of-life care with loved ones/clinicians and documenting them in advance directives). This study will use existing, trusted, and respected social networks to evaluate two conversation-based tools intended to engage underserved... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Sunshine Terrace Foundation, Logan, Utah
Conditions: Advance Care Planning, Advance Directives, Terminal Illness, Chronic Illness, Communication
Register for Updates
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717
Recruiting
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiatio... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: American Fork Hospital / Huntsman Intermountain Cancer Center, American Fork, Utah
Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
NCT03180268
Recruiting
This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: American Fork Hospital / Huntsman Intermountain Cancer Center, American Fork, Utah
Conditions: Intracranial Meningioma, Grade 2 Meningioma
Register for Updates
Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy
NCT06543446
Recruiting
The investigators aim to compare the risk of mortality of Non-implantable carioverter defibrillator (ICD) vs. ICD management in patients with heart failure with reduced ejection fraction (HFrEF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Intermountain Health Care, Inc., Salt Lake City, Utah
Conditions: Heart Failure with Reduced Ejection Fraction
Register for Updates
Shared Decision for Drug Interactions in Oral Anticoagulation
NCT06401863
Recruiting
The purpose of this project is to implement and evaluate a shared-decision making (SDM) tool called DDInteract that was developed to support decision making for drug-drugs interactions while on oral anticoagulants. DDInteract will be implemented in clinics at the University of Utah, University of Colorado and University of Vanderbilt. DDInteract will be launched from within the electronic health record (EHR) retrieving patient-specific risk factors, will calculate the risk of harm, and will allo... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/05/2025
Locations: University of Utah, Salt Lake City, Utah
Conditions: Anticoagulants, Drug Interactions
Register for Updates
Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
NCT06365619
Recruiting
The goal of this clinical trial is to study the impact of Neoadjuvant ipilimumab and nivolumab for melanoma patients that had recurrence during or after adjuvant anti-PD-1 therapy. Participants will receive 2 cycles of treatment prior to their standard of care surgery. After surgery participants will receive standard of care adjuvant therapy and be followed for response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Melanoma
Register for Updates
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
NCT05892614
Recruiting
This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improvement of ILD is the outcome of interest, the study will also evaluate changes in the skin. After initial screening (up to 4 weeks), approximately 25 eligible participants will be randomized 2:2:1 to 1... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: aTyr Investigative Site, Salt Lake City, Utah
Conditions: Interstitial Lung Disease
Register for Updates
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
NCT05732831
Recruiting
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
Conditions: Locally Advanced Solid Tumor
Register for Updates
Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
NCT05723055
Recruiting
The goal of this clinical trial is to study the combination of nivolumab and axatilimab in patients with relapsed/refractory classical Hodgkin Lymphoma. This study will mainly look at if the combination works as expected.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah
Conditions: Hodgkin Lymphoma
Register for Updates
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
NCT05722938
Recruiting
The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with sCAP on invasive mechanical ventilation (IMV). Other objectives are to determine detailed pharmacokinetic (PK) properties of trimodulin in a PK substudy and to determine its pharmacodynamic (PD) properties.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: University of Utah, Salt Lake City, Utah
Conditions: Community-acquired Pneumonia
Register for Updates
M-Vizion™ Macroscopic Radiographic Study
NCT05721859
Recruiting
Study of the patient's subsidence after revision hip arthroplasty by assessing gross stem subsidence in the femoral canal.
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
05/05/2025
Locations: University of Utah Department of Orthopaedics, Salt Lake City, Utah
Conditions: Revision Hip Arthroplasty
Register for Updates
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
NCT05600426
Recruiting
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a... Read More
Gender:
ALL
Ages:
Between 0 years and 25 years
Trial Updated:
05/05/2025
Locations: University of Utah/Primary Children's Hospital, Salt Lake City, Utah
Conditions: Severe Aplastic Anemia
Register for Updates